UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 9, 2025
Mural Oncology plc
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________________________
| | | | | | | | |
|
|
|
|
|
|
|
|
|
Ireland | 001-41837 | 98-1748617 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
|
|
|
10 Earlsfort Terrace Dublin 2, D02 T380, Ireland |
| Not Applicable |
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: +353-1-905-8020
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| | | | | |
|
|
|
|
|
|
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
|
|
|
|
|
|
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Ordinary Shares, nominal value $0.01 | MURA | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On January 9, 2025, Mural Oncology plc (the “Company”) issued a press release titled “Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts”. The Company also made available a copy of an updated corporate presentation, which can be accessed on the Company’s website at https://ir.muraloncology.com/events-and-presentations. A copy of the press release is attached hereto as Exhibit 99.1 and a copy of the corporate presentation is attached hereto as Exhibit 99.2, both of which are incorporated by reference herein. The information contained in, or that can be accessed through, the Company’s website is not a part of this filing.
The information contained under this Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, is being furnished herewith and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| Mural Oncology plc |
|
|
|
|
Dated: January 10, 2025 | By: | /s/ Maiken Keson-Brookes |
|
| Name: | Maiken Keson-Brookes |
|
| Title: | Chief Legal Officer |
